Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers

Fig. 3

Axial midgland sequence showing dynamic contrast-enhanced imaging (DCEI) acquired using T1W-FSE sequences over a 1 min period. Gadolinium-based contrast agent (GBCA) is administered intravenously at an injection rate of 2–3 cc per second; lesion enhancement may appear as early as 10 s following injection. Enhancement of the DIL is shown in frames 4 through 7 (arrows), followed by a washout phase where the signal dissipates

Back to article page